Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study

Area of Science:

• Critical Care Medicine
• Pharmacology
• Hemodynamics

Background:

• Septic shock is a critical condition characterized by circulatory dysfunction.
• Microcirculatory impairment is a key factor in septic shock progression.
• Assessing microcirculatory blood flow is crucial for guiding therapy.

Purpose of the Study:

• To compare the effects of levosimendan versus dobutamine on microcirculatory blood flow in septic shock patients.
• To evaluate changes in microvascular flow index (MFI) as a primary endpoint.
• To investigate the impact of these drugs on small and medium vessel blood flow.

Main Methods:

• Prospective, randomized, double-blind clinical trial involving 40 septic shock patients.
• Patients received either levosimendan (0.2 μg·kg⁻¹·min⁻¹) or dobutamine (5 μg·kg⁻¹·min⁻¹) for 24 hours.
• Sublingual microcirculation assessed using sidestream dark-field imaging; hemodynamic data collected via right heart catheterization.

Main Results:

• Levosimendan group showed significantly higher microcirculatory flow indices (MFIm and MFIs) compared to the dobutamine group.
• Levosimendan led to a greater relative increase in perfused vessel density.
• The heterogeneity index decreased significantly in the levosimendan group, indicating improved flow distribution.

Conclusions:

• Levosimendan (0.2 μg·kg⁻¹·min⁻¹) effectively improved sublingual microcirculatory blood flow in septic shock patients.
• Compared to dobutamine, levosimendan demonstrated superior effects on microcirculatory parameters.
• Findings suggest levosimendan as a potential therapeutic option for enhancing microcirculation in septic shock.